Cancer Causes & Control

, Volume 22, Issue 5, pp 697–714 | Cite as

Brain tumors and hormonal factors: review of the epidemiological literature

  • Anne Cowppli-Bony
  • Ghislaine Bouvier
  • Marjory Rué
  • Hugues Loiseau
  • Anne Vital
  • Pierre Lebailly
  • Pascale Fabbro-Peray
  • Isabelle Baldi
Original paper

Abstract

Background

To date, the etiology of primary tumors of the central nervous system (mainly gliomas and meningiomas) is poorly understood. The role of sex hormones has been suggested, based on clinical, experimental, biological, and epidemiological data.

Objective

To review the epidemiological studies on the relation between hormonal factors and the occurrence of glioma and meningioma, in order to identify new research developments.

Methods

Articles published until September 2010 were selected by considering exogenous and endogenous exposures and specific brain tumors. Standardized information was collected from 20 articles: 15 concerning gliomas and 13 meningiomas.

Results

An increased glioma risk was observed with later menarche and menopause, while a reduced glioma risk was observed with hormone replacement therapy (HRT) and oral contraceptive use, despite duration of use had no effect on risk. Meningioma risk increased after menopause and with HRT use. No clear association was found with pregnancy and breastfeeding.

Conclusion

Results are globally concordant with the biologic hypothesis assuming that female sex hormones are protective against glioma and may increase the risk of meningioma. However, new epidemiological studies should be conducted in order to confirm these associations and to refine the role of hormonal factors in brain etiology.

Keywords

Glioma Meningioma Reproductive history Hormonal replacement therapy Oral contraceptive 

References

  1. 1.
    CBTRUS. CBTRUS Statistical Report: primary brain and central nervous system tumors diagnosed in the United States in 2004–2006 central braintumor registry of the United States, Hinsdale, IL; 2010 [updated 2010; cited 2010 Aug 20]; Available from: http://www.cbtrus.org/2010-NPCR-SEER/CBTRUS-WEBREPORT-Final-3-2-10.pdf
  2. 2.
    Loiseau H, Huchet A, Rue M, Cowppli-Bony A, Baldi I (2009) Epidémiologie des tumeurs cérébrales primitives. Rev Neurol (Paris) 165(8–9):650–670Google Scholar
  3. 3.
    Wrensch M, Minn Y, Chew T, Bondy M, Berger MS (2002) Epidemiology of primary brain tumors: current concepts and review of the literature. Neuro Oncol 4(4):278–299PubMedGoogle Scholar
  4. 4.
    Inskip PD, Linet MS, Heineman EF (1995) Etiology of brain tumors in adults. Epidemiol Rev 17(2):382–414PubMedGoogle Scholar
  5. 5.
    Fisher JL, Schwartzbaum JA, Wrensch M, Wiemels JL (2007) Epidemiology of brain tumors. Neurol Clin 25(4):867–890, viiGoogle Scholar
  6. 6.
    Piper JG, Follett KA, Fantin A (1994) Sphenoid wing meningioma progression after placement of a subcutaneous progesterone agonist contraceptive implant. Neurosurgery 34(4):723–725PubMedCrossRefGoogle Scholar
  7. 7.
    Bickerstaff ER, Small JM, Guest IA (1958) The relapsing course of certain meningiomas in relation to pregnancy and menstruation. J Neurol Neurosurg Psychiatry 21(2):89–91PubMedCrossRefGoogle Scholar
  8. 8.
    Ismail K, Coakham HB, Walters FJ (1998) Intracranial meningioma with progesterone positive receptors presenting in late pregnancy. Eur J Anaesthesiol 15(1):106–109PubMedGoogle Scholar
  9. 9.
    Michelsen JJ, New PF (1969) Brain tumour and pregnancy. J Neurol Neurosurg Psychiatry 32(4):305–307PubMedCrossRefGoogle Scholar
  10. 10.
    Saitoh Y, Oku Y, Izumoto S, Go J (1989) Rapid growth of a meningioma during pregnancy: relationship with estrogen and progesterone receptors-case report. Neurol Med Chir (Tokyo) 29(5):440–443CrossRefGoogle Scholar
  11. 11.
    Wan WL, Geller JL, Feldon SE, Sadun AA (1990) Visual loss caused by rapidly progressive intracranial meningiomas during pregnancy. Ophthalmology 97(1):18–21PubMedGoogle Scholar
  12. 12.
    Roelvink NC, Kamphorst W, Van Alphen HA, Rao BR (1987) Pregnancy-related primary brain and spinal tumors. Arch Neurol 44(2):209–215PubMedGoogle Scholar
  13. 13.
    Deipolyi AR, Han SJ, Parsa AT (2010) Development of a symptomatic intracranial meningioma in a male-to-female transsexual after initiation of hormone therapy. J Clin Neurosci 17(10):1324–1326PubMedCrossRefGoogle Scholar
  14. 14.
    Gazzeri R, Galarza M, Gazzeri G (2007) Growth of a meningioma in a transsexual patient after estrogen-progestin therapy. N Engl J Med 357(23):2411–2412PubMedCrossRefGoogle Scholar
  15. 15.
    Gruber T, Dare AO, Balos LL, Lele S, Fenstermaker RA (2004) Multiple meningiomas arising during long-term therapy with the progesterone agonist megestrol acetate. Case report. J Neurosurg 100(2):328–331PubMedCrossRefGoogle Scholar
  16. 16.
    Vadivelu S, Sharer L, Schulder M (2010) Regression of multiple intracranial meningiomas after cessation of long-term progesterone agonist therapy. J Neurosurg 112(5):920–924PubMedCrossRefGoogle Scholar
  17. 17.
    Speirs V, Boyle-Walsh E, Fraser WD (1997) Constitutive co-expression of estrogen and progesterone receptor mRNA in human meningiomas by RT-PCR and response of in vitro cell cultures to steroid hormones. Int J Cancer 72(5):714–719PubMedCrossRefGoogle Scholar
  18. 18.
    Chamaon K, Stojek J, Kanakis D, Braeuninger S, Kirches E, Krause G et al (2005) Micromolar concentrations of 2-methoxyestradiol kill glioma cells by an apoptotic mechanism, without destroying their microtubule cytoskeleton. J Neurooncol 72(1):11–16PubMedCrossRefGoogle Scholar
  19. 19.
    Lis A, Ciesielski MJ, Barone TA, Scott BE, Fenstermaker RA, Plunkett RJ (2004) 2-Methoxyestradiol inhibits proliferation of normal and neoplastic glial cells, and induces cell death, in vitro. Cancer Lett 213(1):57–65PubMedCrossRefGoogle Scholar
  20. 20.
    Kang SH, Cho HT, Devi S, Zhang Z, Escuin D, Liang Z et al (2006) Antitumor effect of 2-methoxyestradiol in a rat orthotopic brain tumor model. Cancer Res 66(24):11991–11997PubMedCrossRefGoogle Scholar
  21. 21.
    Verzat C, Delisle MB, Courriere P, Hollande E (1990) Influence of host sex on the growth of a human glioblastoma line in athymic mice. Neuropathol Appl Neurobiol 16(2):141–151PubMedCrossRefGoogle Scholar
  22. 22.
    Plunkett RJ, Lis A, Barone TA, Fronckowiak MD, Greenberg SJ (1999) Hormonal effects on glioblastoma multiforme in the nude rat model. J Neurosurg 90(6):1072–1077PubMedCrossRefGoogle Scholar
  23. 23.
    Barone TA, Gorski JW, Greenberg SJ, Plunkett RJ (2009) Estrogen increases survival in an orthotopic model of glioblastoma. J Neurooncol 95(1):37–48PubMedCrossRefGoogle Scholar
  24. 24.
    Carroll RS, Zhang J, Dashner K, Sar M, Black PM (1995) Steroid hormone receptors in astrocytic neoplasms. Neurosurgery 37(3):496–503PubMedCrossRefGoogle Scholar
  25. 25.
    Khalid H, Shibata S, Kishikawa M, Yasunaga A, Iseki M, Hiura T (1997) Immunohistochemical analysis of progesterone receptor and Ki-67 labeling index in astrocytic tumors. Cancer 80(11):2133–2140PubMedCrossRefGoogle Scholar
  26. 26.
    Konstantinidou AE, Korkolopoulou P, Mahera H, Kotsiakis X, Hranioti S, Eftychiadis C et al (2003) Hormone receptors in non-malignant meningiomas correlate with apoptosis, cell proliferation and recurrence-free survival. Histopathology 43(3):280–290PubMedCrossRefGoogle Scholar
  27. 27.
    Korhonen K, Salminen T, Raitanen J, Auvinen A, Isola J, Haapasalo H (2006) Female predominance in meningiomas can not be explained by differences in progesterone, estrogen, or androgen receptor expression. J Neurooncol 80(1):1–7PubMedCrossRefGoogle Scholar
  28. 28.
    Pravdenkova S, Al-Mefty O, Sawyer J, Husain M (2006) Progesterone and estrogen receptors: opposing prognostic indicators in meningiomas. J Neurosurg 105(2):163–173PubMedCrossRefGoogle Scholar
  29. 29.
    Wahab M, Al-Azzawi F (2003) Meningioma and hormonal influences. Climacteric 6(4):285–292PubMedGoogle Scholar
  30. 30.
    Helseth A, Mork SJ, Johansen A, Tretli S (1989) Neoplasms of the central nervous system in Norway. IV. A population-based epidemiological study of meningiomas. APMIS 97(7):646–654PubMedCrossRefGoogle Scholar
  31. 31.
    Preston-Martin S (1989) Descriptive epidemiology of primary tumors of the brain, cranial nerves and cranial meninges in Los Angeles county. Neuroepidemiology 8(6):283–295PubMedCrossRefGoogle Scholar
  32. 32.
    McKinley BP, Michalek AM, Fenstermaker RA, Plunkett RJ (2000) The impact of age and sex on the incidence of glial tumors in New York state from 1976 to 1995. J Neurosurg 93(6):932–939PubMedCrossRefGoogle Scholar
  33. 33.
    Custer BS, Koepsell TD, Mueller BA (2002) The association between breast carcinoma and meningioma in women. Cancer 94(6):1626–1635PubMedCrossRefGoogle Scholar
  34. 34.
    Schneider B, Pulhorn H, Rohrig B, Rainov NG (2005) Predisposing conditions and risk factors for development of symptomatic meningioma in adults. Cancer Detect Prev 29(5):440–447PubMedCrossRefGoogle Scholar
  35. 35.
    Schoenberg BS, Christine BW, Whisnant JP (1975) Nervous system neoplasms and primary malignancies of other sites. The unique association between meningiomas and breast cancer. Neurology 25(8):705–712PubMedGoogle Scholar
  36. 36.
    Seal S, Thompson D, Renwick A, Elliott A, Kelly P, Barfoot R et al (2006) Truncating mutations in the Fanconi anemia J gene BRIP1 are low-penetrance breast cancer susceptibility alleles. Nat Genet 38(11):1239–1241PubMedCrossRefGoogle Scholar
  37. 37.
    Bethke L, Murray A, Webb E, Schoemaker M, Muir K, McKinney P et al (2008) Comprehensive analysis of DNA repair gene variants and risk of meningioma. J Natl Cancer Inst 100(4):270–276PubMedCrossRefGoogle Scholar
  38. 38.
    Benson VS, Pirie K, Green J, Casabonne D, Beral V (2008) Lifestyle factors and primary glioma and meningioma tumours in the million women study cohort. Br J Cancer 99(1):185–190PubMedCrossRefGoogle Scholar
  39. 39.
    Benson VS, Pirie K, Green J, Bull D, Casabonne D, Reeves GK et al (2010) Hormone replacement therapy and incidence of central nervous system tumours in the million women study. Int J Cancer 127(7):1692–1698PubMedGoogle Scholar
  40. 40.
    Hatch EE, Linet MS, Zhang J, Fine HA, Shapiro WR, Selker RG et al (2005) Reproductive and hormonal factors and risk of brain tumors in adult females. Int J Cancer 114(5):797–805PubMedCrossRefGoogle Scholar
  41. 41.
    Blitshteyn S, Crook JE, Jaeckle KA (2008) Is there an association between meningioma and hormone replacement therapy? J Clin Oncol 26(2):279–282PubMedCrossRefGoogle Scholar
  42. 42.
    Cantor KP, Lynch CF, Johnson D (1993) Reproductive factors and risk of brain, colon, and other malignancies in Iowa (United States). Cancer Causes Control 4(6):505–511PubMedCrossRefGoogle Scholar
  43. 43.
    Cicuttini FM, Hurley SF, Forbes A, Donnan GA, Salzberg M, Giles GG et al (1997) Association of adult glioma with medical conditions, family and reproductive history. Int J Cancer 71(2):203–207PubMedCrossRefGoogle Scholar
  44. 44.
    Custer B, Longstreth WT Jr, Phillips LE, Koepsell TD, Van Belle G (2006) Hormonal exposures and the risk of intracranial meningioma in women: a population-based case-control study. BMC Cancer 6:152–160PubMedCrossRefGoogle Scholar
  45. 45.
    Felini MJ, Olshan AF, Schroeder JC, Carozza SE, Miike R, Rice T et al (2008) Reproductive factors and hormone use and risk of adult gliomas. Cancer Causes Control 20:87–96PubMedCrossRefGoogle Scholar
  46. 46.
    Huang K, Whelan EA, Ruder AM, Ward EM, Deddens JA, Davis-King KE et al (2004) Reproductive factors and risk of glioma in women. Cancer Epidemiol Biomarkers Prev 13(10):1583–1588PubMedGoogle Scholar
  47. 47.
    Lambe M, Coogan P, Baron J (1997) Reproductive factors and the risk of brain tumors: a population-based study in Sweden. Int J Cancer 72(3):389–393PubMedCrossRefGoogle Scholar
  48. 48.
    Lee E, Grutsch J, Persky V, Glick R, Mendes J, Davis F (2006) Association of meningioma with reproductive factors. Int J Cancer 119(5):1152–1157PubMedCrossRefGoogle Scholar
  49. 49.
    Preston-Martin S, Monroe K, Lee PJ, Bernstein L, Kelsey J, Henderson S et al (1995) Spinal meningiomas in women in Los Angeles county: investigation of an etiological hypothesis. Cancer Epidemiol Biomarkers Prev 4(4):333–339PubMedGoogle Scholar
  50. 50.
    Schlehofer B, Blettner M, Preston-Martin S, Niehoff D, Wahrendorf J, Arslan A et al (1999) Role of medical history in brain tumour development. Results from the international adult brain tumour study. Int J Cancer 82(2):155–160PubMedCrossRefGoogle Scholar
  51. 51.
    Schlehofer B, Blettner M, Wahrendorf J (1992) Association between brain tumors and menopausal status. J Natl Cancer Inst 84(17):1346–1349PubMedCrossRefGoogle Scholar
  52. 52.
    Silvera SA, Miller AB, Rohan TE (2006) Hormonal and reproductive factors and risk of glioma: a prospective cohort study. Int J Cancer 118(5):1321–1324PubMedCrossRefGoogle Scholar
  53. 53.
    Wigertz A, Lonn S, Hall P, Auvinen A, Christensen HC, Johansen C et al (2008) Reproductive factors and risk of meningioma and glioma. Cancer Epidemiol Biomarkers Prev 17(10):2663–2670PubMedCrossRefGoogle Scholar
  54. 54.
    Wigertz A, Lonn S, Mathiesen T, Ahlbom A, Hall P, Feychting M (2006) Risk of brain tumors associated with exposure to exogenous female sex hormones. Am J Epidemiol 164(7):629–636PubMedCrossRefGoogle Scholar
  55. 55.
    Kabat GC, Park Y, Hollenbeck AR, Schatzkin A, Rohan TE (2011) Reproductive factors and exogenous hormone use and risk of adult glioma in women in the NIH-AARP diet and health study. Int J Cancer 128(4):944–950PubMedCrossRefGoogle Scholar
  56. 56.
    Hochberg F, Toniolo P, Cole P, Salcman M (1990) Nonoccupational risk indicators of glioblastoma in adults. J Neurooncol 8(1):55–60PubMedCrossRefGoogle Scholar
  57. 57.
    Jhawar BS, Fuchs CS, Colditz GA, Stampfer MJ (2003) Sex steroid hormone exposures and risk for meningioma. J Neurosurg 99(5):848–853PubMedCrossRefGoogle Scholar
  58. 58.
    Ryan P, Lee MW, North B, McMichael AJ (1992) Risk factors for tumors of the brain and meninges: results from the Adelaide adult brain tumor study. Int J Cancer 51(1):20–27PubMedCrossRefGoogle Scholar
  59. 59.
    Madigan MP, Troisi R, Potischman N, Dorgan JF, Brinton LA, Hoover RN (1998) Serum hormone levels in relation to reproductive and lifestyle factors in postmenopausal women (United States). Cancer Causes Control 9(2):199–207PubMedCrossRefGoogle Scholar
  60. 60.
    Ernster VL, Wrensch MR, Petrakis NL, King EB, Miike R, Murai J et al (1987) Benign and malignant breast disease: initial study results of serum and breast fluid analyses of endogenous estrogens. J Natl Cancer Inst 79(5):949–960PubMedGoogle Scholar
  61. 61.
    MacMahon B, Trichopoulos D, Brown J, Andersen AP, Cole P, de Waard F et al (1982) Age at menarche, urine estrogens and breast cancer risk. Int J Cancer 30(4):427–431PubMedCrossRefGoogle Scholar
  62. 62.
    Trichopoulos D, Brown J, MacMahon B (1987) Urine estrogens and breast cancer risk factors among post-menopausal women. Int J Cancer 40(6):721–725PubMedCrossRefGoogle Scholar
  63. 63.
    Apter D, Reinila M, Vihko R (1989) Some endocrine characteristics of early menarche, a risk factor for breast cancer, are preserved into adulthood. Int J Cancer 44(5):783–787PubMedCrossRefGoogle Scholar
  64. 64.
    Behl C (2002) Estrogen can protect neurons: modes of action. J Steroid Biochem Mol Biol 83(1–5):195–197PubMedCrossRefGoogle Scholar
  65. 65.
    Shy H, Malaiyandi L, Timiras PS (2000) Protective action of 17beta-estradiol and tamoxifen on glutamate toxicity in glial cells. Int J Dev Neurosci 18(2–3):289–297PubMedCrossRefGoogle Scholar
  66. 66.
    Dhandapani KM, Wade FM, Mahesh VB, Brann DW (2005) Astrocyte-derived transforming growth factor-{beta} mediates the neuroprotective effects of 17{beta}-estradiol: involvement of nonclassical genomic signaling pathways. Endocrinology 146(6):2749–2759PubMedCrossRefGoogle Scholar
  67. 67.
    Yague JG, Munoz A, de Monasterio-Schrader P, Defelipe J, Garcia-Segura LM, Azcoitia I (2006) Aromatase expression in the human temporal cortex. Neuroscience 138(2):389–401PubMedCrossRefGoogle Scholar
  68. 68.
    Inoue T, Sasano H (2004) Possible effects of progesterone on human central nervous system and neurogenic tumors. J Endocrinol Invest 27(1):76–79PubMedGoogle Scholar
  69. 69.
    Dhandapani KM, Brann DW (2007) Role of astrocytes in estrogen-mediated neuroprotection. Exp Gerontol 42(1–2):70–75PubMedCrossRefGoogle Scholar
  70. 70.
    Camacho-Arroyo I, Guerra-Araiza C, Cerbon MA (1998) Progesterone receptor isoforms are differentially regulated by sex steroids in the rat forebrain. Neuroreport 9(18):3993–3996PubMedCrossRefGoogle Scholar
  71. 71.
    Guerra-Araiza C, Villamar-Cruz O, Gonzalez-Arenas A, Chavira R, Camacho-Arroyo I (2003) Changes in progesterone receptor isoforms content in the rat brain during the oestrous cycle and after oestradiol and progesterone treatments. J Neuroendocrinol 15(10):984–990PubMedCrossRefGoogle Scholar
  72. 72.
    Inoue T, Akahira J, Suzuki T, Darnel AD, Kaneko C, Takahashi K et al (2002) Progesterone production and actions in the human central nervous system and neurogenic tumors. J Clin Endocrinol Metab 87(11):5325–5331PubMedCrossRefGoogle Scholar
  73. 73.
    Brinton RD, Thompson RF, Foy MR, Baudry M, Wang J, Finch CE et al (2008) Progesterone receptors: form and function in brain. Front Neuroendocrinol 29(2):313–339PubMedCrossRefGoogle Scholar
  74. 74.
    Chubak J, Tworoger SS, Yasui Y, Ulrich CM, Stanczyk FZ, McTiernan A (2004) Associations between reproductive and menstrual factors and postmenopausal sex hormone concentrations. Cancer Epidemiol Biomarkers Prev 13(8):1296–1301PubMedGoogle Scholar
  75. 75.
    Key TJ, Pike MC, Wang DY, Moore JW (1990) Long term effects of a first pregnancy on serum concentrations of dehydroepiandrosterone sulfate and dehydroepiandrosterone. J Clin Endocrinol Metab 70(6):1651–1653PubMedCrossRefGoogle Scholar
  76. 76.
    Musey VC, Collins DC, Brogan DR, Santos VR, Musey PI, Martino-Saltzman D et al (1987) Long term effects of a first pregnancy on the hormonal environment: estrogens and androgens. J Clin Endocrinol Metab 64(1):111–118PubMedCrossRefGoogle Scholar
  77. 77.
    Musey VC, Collins DC, Musey PI, Martino-Saltzman D, Preedy JR (1987) Long-term effect of a first pregnancy on the secretion of prolactin. N Engl J Med 316(5):229–234PubMedCrossRefGoogle Scholar
  78. 78.
    Cetin I, Cozzi V, Antonazzo P (2008) Infertility as a cancer risk factor—a review. Placenta 29(Suppl B):169–177PubMedCrossRefGoogle Scholar
  79. 79.
    Claus EB, Black PM, Bondy ML, Calvocoressi L, Schildkraut JM, Wiemels JL et al (2007) Exogenous hormone use and meningioma risk: what do we tell our patients? Cancer 110(3):471–476PubMedCrossRefGoogle Scholar
  80. 80.
    Grunberg SM (1994) Role of antiprogestational therapy for meningiomas. Hum Reprod 9(Suppl 1):202–207PubMedGoogle Scholar
  81. 81.
    Grunberg SM, Weiss MH (1990) Lack of efficacy of megestrol acetate in the treatment of unresectable meningioma. J Neurooncol 8(1):61–65PubMedCrossRefGoogle Scholar
  82. 82.
    Grunberg SM, Weiss MH, Spitz IM, Ahmadi J, Sadun A, Russell CA et al (1991) Treatment of unresectable meningiomas with the antiprogesterone agent mifepristone. J Neurosurg 74(6):861–866PubMedCrossRefGoogle Scholar
  83. 83.
    Jaaskelainen J, Laasonen E, Karkkainen J, Haltia M, Troupp H (1986) Hormone treatment of meningiomas: lack of response to medroxyprogesterone acetate (MPA). A pilot study of five cases. Acta Neurochir (Wien) 80(1–2):35–41CrossRefGoogle Scholar
  84. 84.
    Koide SS (1998) Mifepristone. Auxiliary therapeutic use in cancer and related disorders. J Reprod Med 43(7):551–560PubMedGoogle Scholar
  85. 85.
    Lamberts SW, Tanghe HL, Avezaat CJ, Braakman R, Wijngaarde R, Koper JW et al (1992) Mifepristone (RU 486) treatment of meningiomas. J Neurol Neurosurg Psychiatry 55(6):486–490PubMedCrossRefGoogle Scholar
  86. 86.
    Matsuda Y, Kawamoto K, Kiya K, Kurisu K, Sugiyama K, Uozumi T (1994) Antitumor effects of antiprogesterones on human meningioma cells in vitro and in vivo. J Neurosurg 80(3):527–534PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media B.V. 2011

Authors and Affiliations

  • Anne Cowppli-Bony
    • 1
  • Ghislaine Bouvier
    • 1
  • Marjory Rué
    • 2
  • Hugues Loiseau
    • 2
  • Anne Vital
    • 3
  • Pierre Lebailly
    • 4
  • Pascale Fabbro-Peray
    • 5
  • Isabelle Baldi
    • 1
  1. 1.Laboratoire Santé Travail EnvironnementInstitut de Santé Publique d’Epidémiologie et de DéveloppementBordeaux CedexFrance
  2. 2.Service de neurochirurgieCHU PellegrinBordeauxFrance
  3. 3.Service de PathologieCentre Hospitalier et Universitaire de BordeauxBordeauxFrance
  4. 4.GRECAN, Centre François BaclesseUniversité de Caen-Basse NormandieCaenFrance
  5. 5.Unité de Biostatistiques EpidémiologieInstitut Universitaire de Recherche CliniqueMontpellierFrance

Personalised recommendations